The WNT Inhibitor PRI-724 Depletes Endogenous SOX2 and Blocks SOX2 Upregulation by Therapeutic Regimes
Authors:
- Alexander R. SageASAlexander R. Sage
- Daisy V. GonzalezDGDaisy V. Gonzalez
- Briana D. Ormsbee GoldenBGBriana D. Ormsbee Golden
- Ethan MetzEMEthan Metz
- Rebecca E. Oberley-DeeganRORebecca E. Oberley-Deegan
- Peter XiePeter Xie
- Donald W. CoulterDCDonald W. Coulter
- Chittalsinh RauljiCRChittalsinh Raulji
- Grinu MathewGMGrinu Mathew
- Angie RizzinoAngie Rizzino
Open Access
Abstract
Background/Objectives: The stem cell transcription factor SOX2 is expressed in more than 20 types of cancer. SOX2 expression is also elevated by a wide range of clinically used drugs and has been linked causally to drug and radiation resistance. Hence, SOX2 is recognized as an important therapeutic target. This study set out to identify a small molecule inhibitor that reduces SOX2 in a wide range of tumor types. Methods: In this study, the WNT inhibitor, PRI-724 (Foscenvivint), was tested for its ability to downregulate SOX2 in ten tumor cell lines using western blot analysis. We also used western blot analysis to examine whether PRI-724 blocks the upregulation of SOX2 by clinically used drugs and radiation. Additionally, we examined the overall effects of PRI-724 on the transcriptome by performing RNA-Seq and STRING analysis. Results: PRI-724 not only downregulated SOX2 in ten different tumor cell lines representing eight different tumor types, but also blocked the upregulation of SOX2 induced by vemurafenib, gemcitabine and radiation. Besides downregulating SOX2 at the protein and RNA level, without altering the stability of SOX2 RNA, PRI-724 significantly modified the transcriptome. STRING analysis of the upregulated and downregulated genes indicates that PRI-724 altered the expression of genes involved in stress-response pathways, including endoplasmic reticulum (ER) stress. Conclusions: The WNT inhibitor PRI-724 downregulates SOX2 expression in a wide range of tumor cell types and blocks the upregulation of SOX2 by clinically used regimens. PRI-724 also modulates the expression of genes associated with stress-response pathways.Keywords
Funding Information
- Nebraska Department of Health and Human Services (2026-30)
- Nebraska Department of Health and Human Services (2027-34)
- Pediatric Cancer Research Group
- Edna Ittner Pediatric Research Support Fund
This publication has 63 references indexed in Scilit:
- Overexpression of Aquaporin‐1 Promotes Epithelial–Mesenchymal Transition and Cancer Stem Cell Properties via Wnt/β‐Catenin Signaling Pathway in Advanced Breast Cancer CellsMolecular Carcinogenesis, 2025
- Resveratrol suppresses gastric cancer cell proliferation and survival through inhibition of PIM-1 kinase activityArchives of Biochemistry and Biophysics, 2020
- SOX2 mediates cisplatin resistance in small‐cell lung cancer with downregulated expression of hsa‐miR‐340‐5pMolecular Genetics & Genomic Medicine, 2020
- Targeting oncogenic SOX2 in human cancer cells: therapeutic applicationProtein & Cell, 2019
- Elevating SOX2 in prostate tumor cells upregulates expression of neuroendocrine genes, but does not reduce the inhibitory effects of enzalutamideJournal of Cellular Physiology, 2019
- Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancerBiomaterials, 2019
- Sox2 dosage: A critical determinant in the functions of Sox2 in both normal and tumor cellsJournal of Cellular Physiology, 2019
- SOX2 immunity and tissue resident memory in children and young adults with gliomaJournal of Neuro-Oncology, 2017
- Sox2/Oct4: A delicately balanced partnership in pluripotent stem cells and embryogenesisBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2016
- Sox2 promotes tamoxifen resistance in breast cancer cellsEMBO Molecular Medicine, 2013